Sanofi (NASDAQ:SNY) Shares Sold by Jamison Private Wealth Management Inc.

Jamison Private Wealth Management Inc. reduced its position in Sanofi (NASDAQ:SNY) by 0.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,405 shares of the company’s stock after selling 205 shares during the period. Jamison Private Wealth Management Inc.’s holdings in Sanofi were worth $1,695,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. POM Investment Strategies LLC acquired a new position in Sanofi in the 2nd quarter worth about $25,000. Larson Financial Group LLC lifted its position in shares of Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares in the last quarter. Register Financial Advisors LLC purchased a new position in shares of Sanofi during the 1st quarter valued at approximately $29,000. Palisade Asset Management LLC acquired a new stake in Sanofi in the 1st quarter valued at $31,000. Finally, Arrow Financial Corp purchased a new stake in Sanofi in the 2nd quarter worth $35,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

NASDAQ:SNY opened at $54.57 on Wednesday. The company has a market cap of $138.21 billion, a P/E ratio of 27.42, a P/E/G ratio of 1.56 and a beta of 0.60. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97. The company’s 50-day moving average price is $55.95 and its 200-day moving average price is $51.44. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period last year, the company posted $0.95 EPS. On average, sell-side analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the topic of several research analyst reports. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Argus increased their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.